From: Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot study
Adverse events
Any grade
No.(%)
Grade 1/2
Grade 3/4
Any
9 (60.0)
7
2
Mouth ulcer
5 (33.3)
4
1
Elevated liver enzymes
2 (13.3)
0
Dyslipidemia
1 (6.67)
Maculopapule